Bacterial Isolates for IBD Treatment via Microbiota Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) are limited, with no medical cures available and existing therapies primarily focused on controlling symptoms through inflammation reduction. Additionally, approaches like fecal microbiota transplant and rationally selected bacterial cocktails have shown early stumbles, such as the failure of SER-109 in clinical trials.
Innovation Solution
A pharmaceutical composition comprising a plurality of bacterial isolates, including Bacteroides stercoris, Bacteroides cellulosilyticus, Bacteroides uniformis, Subdoligranulum variabile, Anaerostipes hadrus, Odoribacter splanchnicus, Roseburia faecis, Faecalibacterium prausnitzii, Akkermansia muciniphila, Alistipes shahii, and Eubacterium rectale, isolated from the stool of different human donors, is administered to treat or prevent IBD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fecal microbiota transplant is used to restore healthy microbiome, then treatment effectiveness is improved, but patient acceptance and ease of operation deteriorate due to unpalatable nature
Solution Approach 1:
The patent extracts the beneficial microbial components from fecal matter and isolates specific bacterial strains (including Bacteroides stercoris, Bacteroides cellulosilyticus, and other gut-associated bacteria) to create a purified pharmaceutical composition. This extraction process removes the unpalatable fecal material while retaining the therapeutic microbiota, resolving the contradiction between treatment effectiveness and patient acceptance
Solution Approach 2:
The patent creates a standardized copy of healthy microbiota by culturing and formulating specific bacterial isolates in controlled conditions. Instead of using actual fecal transplants, the invention reproduces the beneficial microbial community structure and function through pharmaceutical formulation, maintaining therapeutic efficacy while eliminating the unpalatable aspects of donor feces
2Ease of operation
If rationally selected bacterial cocktails are developed to replace fecal transplants, then patient acceptance is improved, but treatment reliability deteriorates due to early failures in clinical trials
Solution Approach 1:
The patent selects specific bacterial strains with known therapeutic properties for IBD treatment, including Bacteroides stercoris (isolated from healthy human donors), Bacteroides cellulosilyticus, and other gut-associated bacteria. Each strain is chosen for its specific functional properties and ability to colonize the gut environment, creating a targeted formulation rather than a generic mixture, thereby improving treatment reliability
Solution Approach 2:
The patent creates a composite pharmaceutical composition containing multiple bacterial isolates (at least two different strains) in specific formulations. This composite approach combines the synergistic effects of different bacterial species while maintaining standardized production, addressing the reliability issues of previous single-strain or non-standardized cocktails
3Ease of operation
If current IBD therapies focus on reducing inflammation to control symptoms, then ease of operation is improved, but treatment effectiveness deteriorates because no medical cures are available
Solution Approach 1:
Instead of treating the symptom (inflammation) as current therapies do, the patent inverts the approach by targeting the root cause (dysbiosis of the microbiome). The pharmaceutical composition of bacterial isolates restores healthy gut flora, which then naturally reduces inflammation and addresses the underlying disease mechanism, potentially providing a cure rather than just symptom control
Data Source
AI summary
Described herein are compositions and methods for the delivery of microbial therapeutics useful for the treatment of disorders related to intestinal dysbiosis.